VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 20, 2020 | Post-IPO Equity | $33.60M | 1 | Caxton Advantage Life Sciences Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Caxton Advantage Life Sciences Fund | Yes | Post-IPO Equity |